Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Simvastat... ( -- This Approval Creates New Gro...)

Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Simvastatin Tablets

Date:7/31/2008

-- This Approval Creates New Growth Opportunities for the Company -- Company Expects to Exceed Its FY2008 Make Good Target of $5.6 million

CHENGDU, China, July 31 /Xinhua-PRNewswire-FirstCall/ -- Tianyin Pharmaceutical, Co., Inc. (OTC Bulletin Board: TYNP), a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced that it has received approval from the Chinese State Food and Drug Administration (SFDA) to produce Simvastatin Tablets (SFDA approval number H20083478).

Simvastatin is a Statin drug which is used to control hypercholesterolemia and treat coronary heart diseases. This is the only Statin type drug approved by SFDA to treat these conditions and is highly effective, with fewer side effects when compared to other similar drugs. Simvastatin can reduce the mortality rate of coronary heart diseases, coronary artery diseases, and cerebral stroke by 17%, 24% and 25%, respectively. The China Cholesterol Education Program recommends Simvastatin to treat these conditions. Simvastatin is also listed in the National Medical Insurance Program, thus allowing insured patients to receive reimbursement for the costs of this prescription.

Research report from Tulane University published on American Heart Association's Journal of Circulation shows that due to lifestyle changes in China, high levels of hypercholesterolemia and low levels of awareness, treatment, and information regarding same has made cardiovascular disease the leading cause of death in China. As a leading Statin class drug, Simvastatin had total sales of over $190 million in China during 2006. Less than 40% of Simvastatin sold in China's market is produced by domestic manufacturers. Simvastatin Tablets from Tianyin are expected to gain large market share from companies that currently import Simvastatin due to Tianyin's competitive pricing advantages.

Tianyin's Simvastatin Tablets are sold by prescription in hosp
'/>"/>

0

GOOD

Page: 1 2 3
Related medicine news :

1. Viscorp, Inc. Announces Name Change to Tianyin Pharmaceutical Co Inc. and Begins Trading Under the Ticker OTC BB: TYNP
2. Tianyin Pharmaceutical to Present at Roth Third Annual China Discovery Tour in Beijing on May 20, 2008 at 12:40 p.m. Beijing Time
3. Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2008 Third Quarter Earnings Conference Call on Thursday, May 15, 2008 at 9:00 a.m. EDT
4. Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results
5. Tianyin Pharmaceutical Signs Over 60 New Distribution Agreements with 15 Regional Distributors
6. Tianyin Pharmaceutical Co., Inc. Completes Production for Earthquake
7. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
8. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
10. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)

Post Your Comments:

Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Simvastat...( -- This Approval Creates New Gro...),Health